Nexkin Medical Advances in Allergology and Prepares its Commercial Jump to Europe

Nexkin Medical is preparing for its commercial leap in Europe. The Spanish company specializing in allergy is preparing its commercial leap into Europe, with a special interest in the UK and German markets, according to Oscar Matellanes, CEO and co-founder of Nexkin Medical.

The company has regulatory clearance to market its Nexkin Dspt device in Europe. The company has carried out some pilot projects, but it is from now on that the start-up intends to enter the Anglo-Saxon and German markets. Other countries such as France or Italy and even Denmark are also on the horizon.

Nexkin Dspt is a digital device that measures the skin’s reaction to external agents during allergy tests. One of the competitive advantages of the device is that it more accurately analyzes the reaction of patients compared to traditional systems.

The market access strategy consists of the initial sale to “reference centers and opinion leaders” of the specialty, to progressively increase penetration in centers in Europe, as well as to approach multinationals in the sector.

Nexkin Medical has already sold its technology to centers such as the Clínic de Barcelona or the Hospital de Basurto

To accelerate its commercial activity in these countries, the company has opened a round of financing for an amount of more than one million euros, although more details are unknown for the moment.

In 2022, Nexkin Medical carried out the presentation of its technology at the annual congress of the European Association of Allergology and Clinical Immunology (Eaaci) held in Prague. Likewise, the company has validated its product with hospitals in the United Kingdom, Denmark, Italy, and France. “In these countries, together with Germany, we plan to develop new pilots, validations, and clinical trials, as part of our market entry strategy,” said Matellanes.

Also in 2022, Nexkin Medical developed pilots for the analysis of large volumes of allergy data, integration, and validation with Spanish centers such as the Hospital Clínic de Barcelona, ​​Clínica Universidad de Navarra, both in Madrid and Pamplona, ​​Hospital Meixoeiro (Vigo), Basurto Hospital (Bilbao) and Navarra University Hospital (Pamplona). All of them have acquired the company’s technology.

In addition, Nexkin Medical has participated in clinical trials aimed at validating a new intent for use: intradermal drug allergy testing. These clinical trials for intradermal tests will continue in 2023 with the participation of centers such as Hospital De la Cruz Roja (Madrid), Hospital Universitario de Málaga, Clínica Universidad de Navarra, and European centers of reference in drug allergy.

In 2023, the company will continue with the participation of centers such as Hospital De la Cruz Roja (Madrid)

In 2021, the company raised more than €800,000 in a financing round led by Clave Capital, Geroa, and the company’s management team. Of the total volume of the round,  Clave Capital, Geroa, and the management team each contributed €100,000. The objectives of this round were to support and promote the commercialization of the product, reinforce the team, and strengthen digitization.

Nexkin Medical was founded in 2016 by Oscar Matellanes, a telecommunications engineer and MBA. The company is headquartered in San Sebastián and has so far raised around two million euros from private investors and non-dilutive financing.

In August of last year, for example, Nexkin Medical received €1.1 million from the Center for Technological Development and Innovation (Cdti) to be able to optimize, validate its technology and commercialize it.

__

(Featured image by CDC via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.